Provisional Translation from Japanese Original

The Standards for Marketing Approval of Antivertigo Medicines

1. Scope of Antivertigo Medicines

The scope of preparations subject to these standards covers oral medicines (Kampo medicine* formulas are not covered) intended to prevent or relieve symptoms associated with motion sickness, such as dizziness, nausea, and headaches.

*Kampo medicine is traditional Japanese medicine.

2. Approval Standards

The approval standards for antivertigo medicines intended to prevent or relieve symptoms associated with motion sickness (hereinafter referred to as motion sickness drugs) are as follows. For motion sickness drugs and antivertigo medicines other than motion sickness drugs not conforming to these standards, efficacy and safety data and reasons justifying the combination should be submitted; the preparation in question will be reviewed based on these data.

- (1) Types of Active Ingredients
 - (a) The types of active ingredients that may be combined are shown in Table 1.
 - (b) At least one ingredient from either Column I or Group 1 of Column II of Table 1 must be combined.
 - (c) Though the active ingredients in Column I, II, III, IV, V, VI, or VII of Table 1 may all be mutually combined, the types of active ingredients that may be combined in oral liquid preparations should be those in Column I, Group 1 of Column II, Column V, and Column VII.
 - (d) Up to 2 ingredients from each of Column I or V in Table 1 may be included (however, only 1 ingredient from each of Group 1 or 2 of Column V may be combined).One active ingredient each from Column II, III, IV, VI, or VII may be included.
 - (e) Other than the active ingredients in Table 1, vitamins listed in the Appendix may be included if there is a sound basis for their combination and the effect is mild.
- (2) Quantities of Active Ingredients
 - (a) Table 1 shows the maximum single and daily doses for each of the active ingredients listed.
 - (b) When 1 active ingredient listed in either Column I or Group 1 of Column II of Table 1 is used, the lower limit of the single dose of each active ingredient should be half of the maximum single dose.
 - (c) When 2 of the active ingredients in Column I of Table 1 are used, the lower limit of the single dose of each active ingredient should be 1/5th of the maximum single dose. In addition, the sum of the values obtained by dividing the amounts of each active ingredient by their respective maximum single dose should be not less than 0.5 and not more than 1.

- (d) When active ingredients in Column I or Group 1 of Column II of Table are combined mutually, the lower limit of the single dose of each active ingredient should be 1/5th of the maximum single dose. Further, the sum of the values obtained by dividing the amounts of each active ingredient by their respective maximum single dose should be not less than 0.5 and not more than 2.
- (e) The lower limit of the single dose of each active ingredient in Group 2 or 3 of Column II, Column III, Column IV, Column V, or Column VI of Table 1 should be 1/5th of the maximum single dose.
- (f) When 2 ingredients from Column V of Table 1 are combined, the sum of the values obtained by dividing the amounts of each active ingredient by their respective maximum single dose should not exceed 1.
- (g) The lower limit of the single dose of each active ingredient in Column VII of Table 1 should be 1/10th of the maximum single dose.
- (h) The maximum daily dose of each active ingredient listed in the Appendix is as specified in the table.
- (3) Dosage Form

The dosage forms are capsules, granules, pills, fine granules, powders, tablets (including chewable tablets), and oral liquids.

- (4) Dosage and Administration
 - (a) Dosage is by oral administration from 1 to 3 times a day (with the exception of 1 to 4 times a day for single active ingredient preparations containing dimenhydrinate). The time of administration and intervals between doses should be clearly indicated. For medicines designed to be taken twice a day or more, the interval between doses must be at least 4 hours.
 - (b) In principle, dosage for children under 3 years of age is not approved. In the case of preparations containing ethyl aminobenzoate, dosage is not approved for children under 6 years of age, and as for preparations containing promethazine hydrochloride or promethazine methylene disalicylate, dosage for those under 15 years of age is not approved.
 - (c) For capsules, and pills and tablets larger than 6 mm in diameter, dosage for children under 5 years of age is not approved.
 - (d) The maximum single and daily doses for children under 15 years of age is obtained by multiplying the maximum single and daily doses given in Table 1 by the coefficient for each age group given in Table 2.
 - (e) The method of administration must be clearly indicated for chewable tablets.
- (5) Indications

The indications are "prevention and relief of dizziness, nausea, and headache associated with motion sickness."

(6) Packaging Units

In principle, the volume of containers for oral liquids should be the amount for a single dose and should not exceed 30 mL.

Table 1

Column I Difenidol hydrochloride 25 27 Diphenylpyraline hydrochloride 4 12 Diphenylpyraline hydrochloride 50 15 Promethazine hydrochloride 50 15 Promethazine hydrochloride 50 15 Diphenhydramine salicylate 60 186 Dimenhydriniate 50 200 Diphenhydramine tannate 150 450 Fenethazine tannate 30 90 Diphenhydramine furmarte 30 60 Promethazine methylenedisalicylate 30 90 Diphenhydramine maleate 2 6 Pheniramine maleate 30 90 V Scopolamine hydrochloride 2.92 8.75 Oxyphencyclimine hydrochloride 2.92 8.75 Antopine methylbromide 1.6 4.84 Hydrochloride 2.92 8.75 Antopine methylbromide 2.92 8.75 Antopine methylbromide 1.6 4.8 Hyoscyamine methylbromide 2.0 6 Antopine methylbromide 2.5 <	Column		Active ingredient	Maximum single dose (mg)	Maximum daily dose (mg)
Image: Provide the system of the sy	Column I		Difenidol hydrochloride	25	75
Image: Second and the second			Diphenylpyraline hydrochloride	4	12
Image: Promethazine hydrochloride 25 50 Mecitizine hydrochloride 50 77 Diphenhydramine salicylate 60 186 Dimenhydramine salicylate 60 186 Dimenhydramine tannate 50 200 Diphenhydramine tannate 30 90 Diphenhydramine tunate 30 90 Diphenylydramine tunate 60 188 Promethazine methylenedisalicylate 30 60 d/-Chlorpheniramine maleate 4 12 d-Chlorpheniramine maleate 30 90 Diphenhydramine fundente 30 90 Gg Scopolamine hydrochloride 2.5 0.50 Methixene hydrochloride 2.34 7 7 Dicyclomine hydrochloride 2.92 8.75 Arropine methylbromide 10 30 Methixene hydrochloride 2.92 8.75 Arropine methylbromide 10 30 Keylbenactyzium bromide 1.6 4.88 4.92 66 Asistorpine methylbromide 2.0			Diphenhydramine hydrochloride	50	150
Image: Second and the second			Promethazine hydrochloride	25	50
Image: Provide the second se			Meclizine hydrochloride	50	75
Image: Provide the second se			Diphenhydramine salicylate	60	180
Image: Provide the second se			Dimenhydrinate	50	200
Image of the second s			Diphenhydramine tannate	150	450
Image: Interaction of the second se			Fenethazine tannate	30	90
Image Image <th< td=""><td>Diphenylpyraline teoclate</td><td>3</td><td>9</td></th<>			Diphenylpyraline teoclate	3	9
Image: hyperbolic interviewer (hyperbolic) 1000000000000000000000000000000000000			Diphenhydramine fumarate	60	180
Industriant methylic inclusivy methylic 30 30 30 International methylic inclusivy methylic 4 12 4 6 Image: Inclusion of the inclusio			Promethazine methylenedisalicylate	30	60
Image: Provide and			<i>dL</i> Chlornheniramine maleate	4	12
Heritarian 1 2 0 Pheniramine maleate 30 90 Pheniramine maleate 30 90 Scopolamine hydrobromide 0.25 0.50 Oxyphencyclimine hydrochloride 2.34 77 Dicyclomine hydrochloride 10 30 Methixene hydrochloride 2.92 8.75 Atropine methylbromide 2 6 Anisotropine methylbromide 10 30 Scopolamine methylbromide 10 30 Scopolamine methylbromide 10 30 Hyoscyamine methylbromide 10 30 Belladonna extract 20 60 Isopropamide iodide 2.5 7.5 Diphenylpiperidinomethyldioxolan iodide 20 60 Scopolia extract 20 60 Scopola extract 20 60 Scopola extract 20 60 Scopola extract 20 60 Column IV Ethyl aminobenzoate 100 300 <t< td=""><td></td><td></td><td>d-Chlornheniramine maleate</td><td>2</td><td>6</td></t<>			d-Chlornheniramine maleate	2	6
Image: Problem and the instruction of the image: Problem and the ima			Deniramine maleate	2	0
Image: Description Scopolamine hydrobromide 0.25 0.50 Image: Description Oxyphencyclimine hydrochloride 2.34 7 Dicyclomine hydrochloride 10 30 Methixene hydrochloride 2.92 8.75 Atropine methylbromide 10 30 Scopolamine methylbromide 10 30 Scopolamine methylbromide 10 30 Scopolamine methylbromide 0.75 2.25 Metylbenactyzium bromide 10 30 Belladonna extract 20 60 Isopropamide iodide 2.5 7.5 Diphenylpiperidinomethyldioxolan iodide 20 60 Scopolia extract 20 600 Column III Ethyl aminobenzoate 100 300 Column IV Allylisopropylacetylurea 60 180					30
H Oxyphencyclimine hydrochloride 2.34 77 Dicyclomine hydrochloride 10 30 Methixene hydrochloride 2.92 8.75 Atropine methylbromide 2 6 Anisotropine methylbromide 10 30 Scopolamine methylbromide 10 30 Scopolamine methylbromide 1.6 4.8 Hyoscyamine methylbromide 0.75 2.25 Metylbenactyzium bromide 10 30 Belladonna extract 20 60 Isopropamide iodide 2.5 7.5 Diphenylpiperidinomethyldioxolan iodide 20 60 Scopolia extract 20 600 Column III Ethyl aminobenzoate 100 300 Column IV Allylisopropylacetylurea 60		Group I	Scopolamine hydrobromide	0.25	0.50
H ImageDicyclomine hydrochloride1030Methixene hydrochloride2.928.75Atropine methylbromide26Anisotropine methylbromide1030Scopolamine methylbromide1.64.8Hyoscyamine methylbromide0.752.25Metylbenactyzium bromide10300Belladonna extract20600Isopropamide iodide2.57.5Diphenylpiperidinomethyldioxolan iodide20600Scopolia extract20600Scopolia extract20600Scopolia extract20600Scopolia extract20600Scopolia extract20600Scopolia extract200600Column IIIEthyl aminobenzoate100300Column IVAllylisopropylacetylurea60180Bromovalerylurea200600150Timovalerylurea50150Timovalerylurea50150Anhydrous caffeine50150Aminophylline100300			Oxyphencyclimine hydrochloride	2.34	7
H Methixene hydrochloride 2.92 8.75 Atropine methylbromide 2 6 Anisotropine methylbromide 10 30 Scopolamine methylbromide 1.6 4.8 Hyoscyamine methylbromide 0.75 2.25 Methixene hydrochloride 0.75 2.25 Methixene hydrochloride 0.075 2.25 Methixene hydrochloride 0.0 30 Belladonna extract 20 600 Isopropamide iodide 2.5 7.5 Diphenylpiperidinomethyldioxolan iodide 20 600 Scopolia extract 20 600 Scopolia extract 20 600 Scopolia extract 20 600 Scopolia extract 20 600 Column III Ethyl aminobenzoate 100 300 Cerium oxalate 100 300 300 Bromovalerylurea 60 180 300 Bromovalerylurea 50 150 150 Caffeine citrate			Dicyclomine hydrochloride	10	30
H Atropine methylbromide 2 6 Anisotropine methylbromide 10 30 Scopolamine methylbromide 1.6 4.8 Hyoscyamine methylbromide 0.75 2.25 Metylbenactyzium bromide 10 30 Belladonna extract 20 60 Isopropamide iodide 2.5 7.5 Diphenylpiperidinomethyldioxolan iodide 20 600 Scopolia extract 20 600 Column III Ethyl aminobenzoate 100 300 Cerium oxalate 100 300 300 Column IV Allylisopropylacetylurea 60 180 Bromovalerylurea 200 600 150 Caffeine citrate 100 <td></td> <td></td> <td>Methixene hydrochloride</td> <td>2.92</td> <td>8.75</td>			Methixene hydrochloride	2.92	8.75
H Anisotropine methylbromide 10 30 Scopolamine methylbromide 1.6 4.8 Hyoscyamine methylbromide 0.75 2.25 Metylbenactyzium bromide 10 30 Belladonna extract 20 60 Isopropamide iodide 2.5 7.5 Diphenylpiperidinomethyldioxolan iodide 20 60 Scopolia extract 20 60 Column III Ethyl aminobenzoate 100 300 Column IV Allylisopropylacetylaminobenzoate 200 600 Bromovalerylurea 200 600 180 Bromovalerylurea 50 150			Atropine methylbromide	2	6
$\begin{tabular}{ c c c c } \hline \begin{tabular}{ c c c c } \hline \begin{tabular}{ c c } \hline \hline \begin{tabular}{ c c$	Column II	Group II	Anisotropine methylbromide	10	30
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $			Scopolamine methylbromide	1.6	4.8
$\begin{array}{c c c c c c c c c c c c c c c c c c c $			Hyoscyamine methylbromide	0.75	2.25
$\begin{tabular}{ c c c c c c } \hline Belladonna extract & 20 & 60 \\ \hline Isopropamide iodide & 2.5 & 7.5 \\ \hline Diphenylpiperidinomethyldioxolan iodide & 20 & 60 \\ \hline Scopolia extract & 100 & 300 \\ \hline Column III & Ethyl aminobenzoate & 100 & 300 \\ \hline Column IV & Ethyl p-piperidinoacetylaminobenzoate & 200 & 600 \\ \hline Column IV & Allylisopropylacetylurea & 60 & 180 \\ \hline Bromovalerylurea & 200 & 600 \\ \hline Caffeine citrate & 100 & 300 \\ \hline Caffeine citrate & 100 & 300 \\ \hline Anhydrous caffeine & 50 & 150 \\ \hline Aminophylline & 100 & 300 \\ \hline \end{tabular}$			Metylbenactyzium bromide	10	30
$\begin{tabular}{ c c c c c } \hline Isopropamide iodide & 2.5 & 7.5 \\ \hline Diphenylpiperidinomethyldioxolan iodide & 20 & 60 \\ \hline Scopolia extract & 20 & 60 \\ \hline Scopolia extract & 20 & 60 \\ \hline Scopolia extract & 20 & 60 \\ \hline \\ $			Belladonna extract	20	60
Diphenylpiperidinomethyldioxolan iodide2060Scopolia extract2060Scopolia extract2060EthylPapaverine hydrochloride3090Column IIIEthyl aminobenzoate100300Column IVEthyl p-piperidinoacetylaminobenzoate100300Column IVAllylisopropylacetylurea60180Bromovalerylurea200600Caffeine50150Caffeine citrate100300Anhydrous caffeine50150Aminophylline100300			Isopropamide iodide	2.5	7.5
Scopolia extract2060H O O OPapaverine hydrochloride3090Column IIIEthyl aminobenzoate100300Column IVEthyl aminobenzoate100300Column IVAllylisopropylacetylaminobenzoate200600Column IVAllylisopropylacetylurea60180DCaffeine50150Anhydrous caffeine50150Aminophylline100300			Diphenylpiperidinomethyldioxolan iodide	20	60
Head BogPapaverine hydrochloride3090Column IIIEthyl aminobenzoate100300Column IVEthyl p-piperidinoacetylaminobenzoate100300Column IVAllylisopropylacetylurea60180Bromovalerylurea60180Caffeine50150Caffeine citrate100300Anhydrous caffeine50150Aminophylline100300			Scopolia extract	20	60
$\begin{array}{c c c c c c c c c c c c c c c c c c c $		Group III	Papaverine hydrochloride	30	90
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Column III Column IV		Ethyl aminobenzoate	100	300
$\begin{array}{c c c c c c c c c c c c c c c c c c c $			Cerium oxalate	100	300
Column IVAllylisopropylacetylurea60180Bromovalerylurea200600DescriptionCaffeine50150Caffeine citrate100300Anhydrous caffeine50150Aminophylline100300			Ethyl p-piperidinoacetylaminobenzoate	200	600
Image: Constraint of the second sec			Allylisopropylacetylurea	60	180
N minophyllineCaffeine50150N minophylline100300100300100300	Column V	Group I	Bromovalerylurea	200	600
ECaffeine citrate100300SAnhydrous caffeine50150Aminophylline100300			Caffeine	50	150
Image: DescriptionImage: State Stat			Caffeine citrate	100	300
Aminophylline 100 300			Anhydrous catterne	50	150
		II dno.	Aminophylline	100	300
Diprophylline 100 300			Diprophylline	100	300
5Theophylline100300	Gr		Theophylline	100	300
Column VI Sodium bicarbonate 1,000 3,000	Column VI		Sodium bicarbonate	1,000	3,000
Column VII Mentha oil 5 15	Column VII		Mentha oil	5	15
<i>u</i> -vienuion 50 90 <i>l</i> -Menthol 30 90				30	90

Table 2

Age	Coefficient
15 years old and over	1
11 years old-Under 15	2/3
7 years old-Under 11	1/2
3 years old-Under 7	1/3

Appendix

Ingredients	Maximum daily dose (mg)
Vitamin B ₁ , its derivatives, and their salts	25
Vitamin B ₂ , its derivatives, and their salts	12
Vitamin B ₆ , its derivatives, and their salts	50
Nicotinamide	60
Calcium panthothenate	30